Text this: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

 _    _    _    _              _    _     ______  
| || | || | || | ||     ___   | || | ||  /_____// 
| || | || | || | ||    /   || | || | ||  `____ `  
| \\_/ || | \\_/ ||   | [] || | \\_/ ||  /___//   
 \____//   \____//     \__ ||  \____//   `__ `    
  `---`     `---`       -|_||   `---`    /_//     
                         `-`             `-`